Core Insights - Assembly Biosciences, Inc. is progressing well with its antiviral portfolio, expecting key clinical data sets in 2025, including interim Phase 1b data for ABI-5366 and ABI-1179 in fall 2025 [2][3] Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $91.0 million, down from $112.1 million as of December 31, 2024, with projections to fund operations into mid-2026 [12] - Revenue from collaborative research with Gilead was $9.4 million for Q1 2025, an increase from $5.8 million in Q1 2024, attributed to increased research and development spending and collaboration funding [12] - Research and development expenses rose to $14.9 million in Q1 2025 from $11.9 million in Q1 2024, primarily due to increased spending on ABI-6250 and ABI-5366 [12] - General and administrative expenses slightly decreased to $4.5 million in Q1 2025 from $4.6 million in Q1 2024 [12] - The net loss attributable to common stockholders was $8.8 million, or $1.17 per share, for Q1 2025, compared to a net loss of $9.1 million, or $1.66 per share, for the same period in 2024 [12] Clinical Development Updates - Ongoing clinical studies for four candidates are on track, with data expected in 2025, including interim Phase 1b data for ABI-5366 and ABI-1179 anticipated in fall 2025 [1][4] - The company plans to run concurrent studies for ABI-5366 and ABI-1179, evaluating weekly and monthly oral dosing in participants with recurrent genital herpes over a 28-day period [8] - In Q3 2025, data from a Phase 1a study in healthy participants for ABI-6250 will be assessed for safety and pharmacokinetic measures [8] - Efficacy, safety, and pharmacokinetic data from a Phase 1b study for ABI-4334 in chronic HBV infection is expected in the first half of 2025 [8] Upcoming Conferences - Assembly Biosciences presented multiple abstracts at various conferences, including ICAR, ESCMID, and EASL in 2025, showcasing data on its antiviral candidates [8]